ETHEX Corporation is recalling one lot of 60 mg morphine sulfate tablets due to a risk of overdose. The tablets were manufactured with double the dose of morphine sulfate that is on the label, which could cause serious adverse reactions.

The lot affected by the recall is number 91762. No additional lots are being recalled.

The morphine tablets were released between April 15 and April 27, 2008. They are under the ETHEX label.

As with all opioid medication, the consequences of an overdose can be fatal. An overdose of morphine may result in difficulty breathing and lowered blood pressure.

To this date, the U.S. Food and Drug Administration (FDA) has not received any reports of adverse side effects.

Defective drug attorneys are working to help prevent serious consequences of faulty prescription medication by holding drug manufactures responsible for their negligence.

On March 25^{th, California regulators delayed the electronic tracking of prescription drugs for two years. The California State Board of Pharmacy voted 12-0 to allow prescription drug manufacturers, distributors and pharmacies an additional two years to begin electronically tracking prescription drugs from the manufacturer to the patient.The requirement was already delayed by the California State Legislation in 2007. Now, the pharmaceutical industry has until January 1, 2011. The delay is intended to allow the pharmaceutical industry time to set up computer systems that would comply with the first ever requirement to track prescriptions.}

The requirement was instituted in California after a recall of fake Lipitor.

There are defective drug attorneys currently working on cases that involve the serious and fatal illnesses that result from defective drugs.

The United States Food and Drug Administration (FDA) announced on March 14^{th that it is taking action to stop the import of Heparin into the United States. The active ingredient of Heparin is manufactured by Scientific Protein Laboratories LLC., which has headquarters in both Wisconsin and China.}

A major recall of Heparin was announced in January, 2008. Since then, hundreds of allergic reactions and at least 19 deaths have been reported in association with Heparin use.

A spokesperson for the FDA has announced that since the end of February, no new deaths have been reported due to adverse reactions to Heparin.

The Heparin that is being stopped at the borders is manufactured by Baxter International, Inc. of Wisconsin. Baxter reports that they have not isolated the contamination, so it cannot determine if the contaminated Heparin was manufactured in their Chinese facility.

Defective drug attorneys are currently at work to help those who have faced devastating consequences due to contaminated Heparin.